Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164246 | 0.83 | KMT2A (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL7868885 | 0.83 | KMT2A (0.57) | ALDH1A1KMT2ALMNAGAAPAX8 | |
| SCHEMBL11452472 | 0.83 | ALDH1A1 (0.62) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL3483301 | 0.80 | PSMD10 (0.41) | ALDH1A1KMT2AMEN1GAA | |
| SCHEMBL30850500 | 0.80 | KMT2A (0.49) | ALDH1A1CYP3A4CYP2C9CYP2C19KMT2A | |
| SCHEMBL18530452 | 0.79 | PSMD10 (0.40) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL31682038 | 0.78 | HDAC8 (0.41) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL6328499 | 0.78 | HDAC8 (0.41) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL22029384 | 0.78 | HDAC8 (0.41) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL29223514 | 0.78 | HDAC8 (0.41) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1858844-A4 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| EP-1858844-A1 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006099077-A1 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | FFAR2, PPARG, PPARA | ALDH1A1 3241/4885CYP3A4 1124/4885CYP2C9 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.